Figure S2. Consort diagram illustrating the flow of participants through each stage of the randomized trial, from enrollment to final analysis.
Figure S2.

Non-Small Cell Carcinoma, Stage IV
EGFR exon 19 deletion
or Exon 21 point mutation
ECOG PS 0~2
n=110

Randomization
stratified by
ECOG 0~1 vs. 2
and
EGFR mutation e19 vs. e21

Placebo
twice daily
up to 2 years
n=55

Erlotinib 22 (40.0%)
Gefitinib 33 (60.0%)

Progressed 52 (94.6%)
Not progressed 2 (3.6%)
Lost to follow up 1 (1.8%)

Expired 46 (83.6%)
Survive 7 (12.7%)
Lost to follow up 2 (3.6%)

Nicotinamide
500mg twice daily
up to 2 years
n=55

Erlotinib 23 (41.8%)
Gefitinib 32 (58.2%)

Progressed 50 (90.9%)
Not progressed 5 (9.1%)
Lost to follow up 0 (0%)

Expired 38 (69.1%)
Survive 15 (27.3%)
Lost to follow up 2 (3.6%)